[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621887":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":45,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Instituto Valenciano de Infertilidad, IVI Alicante","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Poor responders undergoing ovarian reactivation StemCell Regenera",null,"Women who present a profile of poor responders meaning they have a poor response towards the ovarian stimulation treatment, yielding a low number of oocytes after oocyte retrieval and moreover want to undergo the ovarian reactivation treatment StemCell Regenera.",[13],"Combination Product: Platelet Rich Plasma + BMDSCs mobilization",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"COMBINATION_PRODUCT","Platelet Rich Plasma + BMDSCs mobilization","This intervention entails, in addition to routine platelet-rich plasma (PRP) isolation, prior mobilization of bone marrow derived stem cells into the peripheral blood using filgrastim, a granulocyte colony-stimulating factor. Consequently, the patient benefits both from the stem cells and their paracrine effects on the ovaries, as well as from the direct effects of intraovarian PRP instillation. Overall, this approach provides multiple benefits derived from two distinct biological sources.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Manuel Muñoz Cantero, MD","CONTACT","+34 966012490","Manuel.Munoz@ivirma.com",[27],{"facility":28,"status":10,"city":29,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"IVIRMA Alicante","Alicante","03015","Spain","ES",{"type":34,"coordinates":35},"Point",[36,37],-0.48149,38.34517,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":41,"phoneExt":10,"email":42},"+34 966 012 490","manuel.munoz@ivirma.com",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[46,49],{"name":47,"class":48},"BTI Biotechnology Institute S.L","UNKNOWN",{"name":50,"class":6},"Fundación IVI","100621887","proteomic-and-biological-characterisation-of-plasma-for-the-study-of-changes-following-ovarian-reactivation-treatment-100621887",false,"NCT07376460","Proteomic and Biological Characterisation of Plasma for the Study of Changes Following Ovarian Reactivation Treatment","Biological and Proteomic Characterisation of Platelet-rich Plasma (PRP) Before and After Mobilisation of Haematopoietic Stem Cells in Peripheral Blood From Women With Low Ovarian Response (Low Responders) and in Vitro Evaluation in Human Ovarian Cell Models","Inclusion Criteria:\n\n* Patients aged between 18 and 43.\n* Patients diagnosed with poor ovarian response (POR) or low ovarian reserve according to Bolonia criteria (ESHRE).\n* Patients who are indicated for a StemCell Regenera procedure with the use of granulocyte colony-stimulating factors (Filgrastim).\n* Patients who agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients over the age of 43.\n* Patients with only one ovary.\n* Patients with an autoimmune or haematological disorder.\n* Patients currently undergoing treatment with anticoagulant drugs.\n* Patients who are allergic to Filgrastim, the granulocyte colony-stimulating factor.","FEMALE","18 Years","43 Years",{"count":62,"type":63},10,"ESTIMATED","OBSERVATIONAL","The samples used in PRGF treatments owe their effectiveness to the handling, concentration, and preservation of their components, which explains why samples obtained with different platelet-rich plasma preparation systems may vary. At IVIRMA Group, we employ the closed system PRGF-Endoret to process these samples for StemCell Regenera samples obtained after mobilizing stem cells with granulocyte colony-stimulating factor stimulators. According to current regulations, PRP samples are considered medicinal products by AEMPS, requiring knowledge of the composition of processed samples to be administered to the patient. The study and quantification of samples used in StemCell Regenera treatments aim to understand how stem cell mobilization performed through this technique influences the characteristics of PRGF-Endoret. In this context, the present project aims to systematically analyse the proteomic profile of PRP\u002FPRGF before and after haematopoietic stem cell mobilisation in poor-responder patients, and to evaluate its biological impact in vitro using human ovarian cell models. This approach will enable the identification of key factors involved in ovarian activation and regeneration, thereby providing a mechanistic basis for optimising regenerative therapies applied in clinical reproductive medicine. Furthermore, it will contribute scientifically relevant insights to the field of research and to patients themselves.",[67,68],"Poor Ovarian Response","Ovarian Reactivation",[70,71,72,73,74,75,76,77,78],"Poor ovarian response","ovarian reactivation","StemCell Regenera","ovarian rejuvenation therapy","ovarian failure","Stem cell mobilization","PRP","PRGF","Bone Marrow Derived Stem Cells (BMDSC)","NOT_YET_RECRUITING","2026-02-02",{"date":82,"type":83},"2026-02-04","ACTUAL",{"date":85,"type":63},"2026-02",{"date":87,"type":63},"2026-06",{"name":5,"class":6},1]